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Abstract
Uromodulin kidney disease (UKD) is a subtype of autosomal dominant tubulointerstitial kidney
disease (ADTKD), and is a rare cause of renal failure and gout in young people. Although it is
inherited in an autosomal dominant fashion, the gene mutation exhibits variable expressivity
so the phenotype varies dramatically among affected individuals. While it is rare, it is important
for physicians in the primary care setting to be able to recognize the disorder, initiate proper
workup, and refer patients to nephrology teams that are equipped to manage the long-term
needs of these patients. Eventually, most will progress to renal failure with necessary renal
dialysis or kidney transplant. Kidney transplant is curative as the new kidney does not have the
defective tubule cell gene. The case series that follows highlights the variable presentations of
the disorder among members of the same family and the necessary long-term follow-up that
will often be handled by the primary care provider in conjunction with the specialist team.

Categories: Family/General Practice, Internal Medicine, Nephrology
Keywords: uromodulin kidney disease, familial juvenile hyperuricemic nephropathy, autosomal
dominant tubulointerstitial kidney disease, gout, renal failure, end stage renal disease, esrd (end stage
renal disease)

Introduction

Received 02/04/2019
Review began 02/07/2019
Review ended 03/16/2019
Published 03/19/2019
© Copyright 2019
Wheeler et al. This is an open access

Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a group of three rare genetic
diseases that share a common feature of slowly declining kidney function starting in
adolescence or young adulthood and leading to end-stage renal disease (ESRD). Other features
common to all three subtypes include: bland urine sediment with signs of chronic kidney
disease (CKD) and the possibility of renal medullary cysts. The most common subtype is
uromodulin kidney disease (UKD) caused by mutations in the uromodulin (UMOD) gene that
encodes uromodulin (Tamm-Horsfall protein). Defective uromodulin cannot be exported and so
accumulates inside renal tubule cells and leads to cell death. UKD is also characterized by
hyperuricemia and early-onset gout, although these may not be seen in all patients with this
genetic subtype. The second subtype is Mucin-1 kidney disease (MKD) caused by mutations in
the MUC1 gene that causes renal failure without other specific findings. The rarest form is
caused by renin (REN) mutations (ADTKD-REN) and is characterized by anemia in childhood,
hypotension, mild hyperkalemia, and hyperuricemia [1].
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Case Presentation
This report follows members of a family with documented UKD (Figure 1).
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FIGURE 1: Family with uromodulin kidney disease
M: Mother, S1: son, D1: daughter, GD1/2/3: granddaughter 1/2/3, GGD1: great-granddaughter,
GGGD1: great-great-granddaughter

Patient S1 had gout and refractory hypertension for many years before being clinically
diagnosed with a genetic kidney disorder in 1975. His mother (M), who is thought to have
carried the UMOD mutation as well, had hypertension without gout and died at the age of 86
years. One of his sisters (D1) was also diagnosed with the disorder but little information about
the clinical onset of disease in her family is available. In 1978, his three children
(granddaughter (GD)1, 2, and 3) were tested and diagnosed using urine analysis and serum uric
acid and creatinine levels. When it became available, genetic testing was done on two members
of the family (GD2, great-granddaughter (GGD1)) and it found UMOD gene mutations. The
table describes the clinical differences among the family members (Table 1).
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M

Unknown

-

-

No

Yes

86

S1

47

42

47

Yes

Yes

54

GD1

17

42

44

Yes

Yes

-

GD2

16

45

46

Yes

Yes

-

GD3

8

33

36

Yes

Yes

-

GGD1

12

-

-

No

Yes

-

GGGD1

12

-

-

No

No

-

Hypertension

Age at
death

TABLE 1: Variable presentations of uromodulin kidney disease in members of a
family
M: Mother, S1: son, D1: daughter, GD1/2/3: granddaughter 1/2/3, GGD1: great-granddaughter, GGGD1: great-great-granddaughter

The severity of gout varies greatly from one member to another and some have hyperuricemia
without gout. GGD1 is 49-years-old and has not yet required dialysis but her kidney function
has declined to the point that she is eligible to be placed on the kidney transplant list. GD1, 2,
and 3 all had successful kidney transplants which have effectively cured their hyperuricemia
and gout. Since the disease is related to an intrinsic renal cell mutation, kidney transplant cures
the disease without possible recurrence. They remain on blood pressure medications to protect
the transplanted kidney.

Discussion
While all three subtypes of ADTKD are rare, ~400 affected families have been identified in the
United States. Early recognition of these patients ensures proper follow-up and management.
Clinical suspicion for UKD should be raised in a young person with elevated serum creatinine,
hyperuricemia or precocious gout, or hypertension. Due to the absence of hematuria or
proteinuria, urinalysis is not helpful in diagnosis. As with any genetic disorder, taking a
thorough family history is vital. De novo mutations resulting in UKD are very rare, so patients
will usually have a strong family history of gout, chronic kidney disease, or kidney transplants.
Patients should be referred for genetic testing to determine the mutations that are involved.
Since disease severity, rate of progression, and end-point varies dramatically even among
patients within the same family, management is determined on a case by case basis and
involves symptomatic treatment. Patients with hyperuricemia or gout are started on allopurinol
or febuxostat. Likewise, anemia, hyperphosphatemia, hypertension, and other manifestations
of CKD are treated as they arise using the same guidelines as in patients without UKD. Unlike in
proteinuric CKD, there has been no evidence that angiotensin converting enzyme inhibitors or
angiotensin receptor blockers slow progression of CKD in patients with UKD. There are trials
that show slowed progression to ESRD in kidney disease patients when they are started on
allopurinol early in the disease course [2]. However, the results were not specific to UKD
patients and there have not been adequate trials in this population. While there is variability in
age of onset, UKD will almost invariably progress to ESRD. Preemptive renal transplantation in
adults is considered when the glomerular filtration rate (GFR) is <20 mL/min/1.73 m2. A renal
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transplant is considered curative. Dialysis will need to be considered if donor kidney is not
available and GFR drops enough that signs and symptoms of kidney failure become apparent
(usually Stage 5 CKD) [3].

Conclusions
Ultimately, genetic diagnosis and eventual renal transplant will happen at an established
medical center capable of providing these services, but long-term management will often fall to
the primary care physician. Optimal control of hypertension, hyperuricemia, and kidney
function will determine a patient’s quality of life and future development of comorbidities
secondary to their diagnosis.
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